In recent years there have been several potentially life-saving medications approved for cancer treatment, including targeted molecular entities and biologics such as Opdivo (nivolumab) and Keytruda (pembrolizumab). Oncology drugs remain a pharmaceutical priority and investments into cancer account for 30% of all pre-clinical and phase 1 clinical development expenditures. There is an impressive list of close to 800 drugs and vaccines currently in the industry-wide development pipeline, many with promising results in early-stage clinical trials. However by historical measures only 10% or fewer of these drugs will ever make it through FDA approval and become part of routine patient care.Read More
Biomarker projects are critical to drug development programs and demonstrating the medical value of therapies. In the planning phase of clinical development, researchers are often looking to achieve the following:
• Clinical researchers want a good understanding of the expected costs of a therapy program and the timelines involved.
• Clinical researchers want to know as early as possible which biomarker and indication combination works best to advance into clinical trials.
When you have multiple potential biomarkers and indications to evaluate for clinical development, you require flexible and fast screening projects to characterize the expression of specific markers in different tumor tissue.Read More
Scientists Prime The Immune System As A Powerful Cancer Weapon
Review of ASCO starting with the summary of a proof-of principle study presented by NCI answering the question if T-cells could be utilized to fight solid tumors.
Our immune systems can unmask tumours and cure cancer, experts say, calling immuno-oncology the biggest breakthrough in years
Review of cancer immunotherapy study results from several drug companies recently presented at ASCO conference including comments to the status of Immunotherapy by several oncology experts from pharmaceutical industry and academic research such as David Hafler (Yale University), Dr. Roy Baynes (senior vice-preseident of clinical research at Merck) and Michael Giordano (Head of Oncology at BMS).
Pharma vies to unleash immune system power on cancer
An overview of ongoing cancer immunotherapy trials and related achievements of the major drug companies chasing to get a share of the estimated enormous market potential of immuno-oncology drugs.
Nearly every day there seems to be exciting news or developments in the field of immunotherapy and immuno-oncology. Not only can you read all about immunotherapy research in leading scientific journals (1), but the mainstream media now reports on the latest immunotherapy clinical trial results from pharmaceutical companies.
But what exactly is immunotherapy and what technologies are needed to realize its full potential for the treatment of cancer? Throughout this whitepaper, Definiens will answerthose questions as well as provide insight into other commonly asked questions about immunotherapy:
- Why is it predicted that 60% of cancer treatments will be based on immunotherapy in the next 10 years?
- What are some of the more common approaches to immunotherapy today?
- What will be needed to accurately identify patients that will respond to immunotherapy treatment?
- How can knowing a patient’s immune status predict long-term treatment success?
- How is the use of Tissue Phenomics™ enabling effective clinical decision-making in oncology?
Download your copy of An Introduction To Immunotherapy And The Promise Of Tissue Phenomics™ to learn more.Read More
Dr. Rosenberg Discusses the Curative Potential of Cancer Immunotherapy
In this video, Dr. Steven A Rosenberg will introduce you to NCIs recently published developments describing how they used exomic sequencing to discover and isolate the immunogenic mutations to use in cancer immunotherapy.
Will Cancer Immunotherapy Open a New Era in the Treatment of Cancer?
You will learn in this video how Dr. George Coukos assesses the present and future of immuno-oncology highlighting the value and utilization of checkpoint inhibitors and cell-based therapeutics.
ITOC 2014: Toll Like Receptor 7 Agonists for Cancer Immunotherapy
Watch Dr. Stefan Enders describe two approaches that redirect the body’s own immune system to attack cancer. The first involves utilizing TLR7 receptors to activate NK cells to kill cancerous tumors. The second approach involves activating the immune system while down-regulating production of proteins that tumor cells need to survive.
Dr. Balar on Immunotherapy Treatment in Bladder Cancer
Immunotherapy has been used in treating bladder cancer for a while now. Learn from Dr. Arjun Balar as he discusses how the checkpoint inhibitors CTLA-4 and PD-1 are changing the landscape of immunotherapy for treatment of invasive bladder cancer.